Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

...

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

...

menu
menu